While it is commonly understood that a difficult childhood can lead to mental health issues, research has now exposed deeper, more troubling impacts of early life adversity: that these experiences can reshape the brain and body at a cellular level. Physiological effects like these are at the core of the McGill-Douglas-Max Planck Institute of Psychiatry International Collaborative Initiative in Adversity and Mental Health (AMH Initiative).
Published on: 11 Jan 2024
In line with our commitment to advancing brain research excellence at McGill, HBHL is happy to introduce five exceptional recruits who have recently joined McGill across three different faculties. These talented individuals have received funding through HBHL's New Recruit Start-Up Supplements program, which provides critical supplementary funding to McGill's hiring faculties, empowering them to attract standout faculty members whose research aligns with HBHL's scientific priorities.
Category:
Published on: 20 Sep 2023
Type 1 diabetes, rheumatoid arthritis, and cancer are just some of the disorders associated with specific genes not “turning on” and “turning off” as they should. By using new CRISPR/Cas9 genome editing technology, in a recent paper in Nature Communications, McGill University researchers have described a new technique that scientists across the world can potentially use to explore novel ways of treating diseases associated with dysregulation in DNA methylation.
Category:
Published on: 9 Nov 2021
Many of the drugs and medicines that we rely on today are natural products taken from microbes like bacteria and fungi. Within these microbes, the drugs are made by tiny natural machines – mega-enzymes known as nonribosomal peptide synthetases (NRPSs). A research team led by McGill University has gained a better understanding of the structures of NRPSs and the processes by which they work.
Category:
Published on: 30 Apr 2020
Depression is a common psychiatric disorder and one of the leading causes of disability worldwide. Antidepressants are the first-line treatment for moderate to severe major depressive episodes. Despite their effectiveness, only 40% of patients respond to the first antidepressant they try. A recent paper in Nature Communication strongly suggests that a particular protein, GPR56, is involved in the biology of depression and the effect of antidepressants.
Category:
Published on: 8 Apr 2020
An international team, that includes researchers from McGill, has completed the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment.
Category:
Published on: 5 Feb 2020
The Consortium for Industrial Research and Innovation in Medical Technologies, MEDTEQ, and the Healthy Brains for Healthy Lives (HBHL) initiative of McGill University are pleased to announce a joint agreement that will harmonize the process of developing research and innovation projects related to medical technologies.
Category:
Published on: 3 Oct 2018
